The influence of ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell lines in vitro

Acta Poloniae Pharmaceutica - Drug Research

Volumn 68, Issue 6, 2011, Pages 859-865

  Kloskowski, Tomasz ^a   Gurtowska, Natalia ^a   Nowak, Monika ^a   Joachimiak, Romana ^a   Bajek, Anna ^a   Olkowska, Joanna ^a   Drewa, Tomasz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Ciprofloxacin; Glioblastoma; Hepatic cancer; In vitro cytotoxiciy; Lung cancer; Melanoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CIPROFLOXACIN; TRYPAN BLUE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA B16; MOUSE; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, NON-SMALL-CELL LUNG; CELL SHAPE; CELL SURVIVAL; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; RATS; TIME FACTORS;

EID: 80355127343     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Louie J.T.: Can. Med. Assoc. J. 150, 669 (1994).
2. Sipsas N., Kosmas C., Ziakas P. et al.: Scand. J. Infect. Dis. 39, 786 (2007).
3. Motoc M., Verdes D., Andrei A. et al.: JK Practitioner 10, 281 (2003).
4. Randall C., Walker M.D.: Mayo Clin. Proc. 74, 1030 (1999).
5. Haraguchi S., Hioki M., Yamashita K. et al.: Surg. Today 37, 282 (2007).
6. Dalhoff A.: Infection 33 (Suppl 2), 55 (2005).
7. Drlica K.: Curr. Opin. Microbiol. 2, 504 (1999).
8. Smart D.J., Halicka H.D., Traganos F. et al.: Cancer Biol. Ther. 7, 113 (2008).
9. Herbold B.A., Brendler-Schwaab S.Y., Jurgen H.: Mutat. Res. 498, 193 (2001).
10. Kloskowski T., Gurtowska N., Drewa T.: Pulm. Pharmacol. Ther. 23, 373 (2010).
11. Gurtowska N., Kloskowski T., Drewa T.: Med. Sci. Monit. 16, 218 (2010).
12. Kloskowski T., Olkowska J., Drewa T.: Acta Pol. Pharm. Drug Res. 67, 345 (2010).
13. Baldea I., Mocan T., Cosgarea R.: Exp. Oncol. 32, 200 (2009).
14. Drewa T., Krawczyk A., Gospodarek E., Jachna-Sawicka K., Bugalski R., Kierzenkowska-Mila C.: Acta Pol. Pharm. Drug Res. 63, 543 (2006).
15. Olszewska-Słonina D., Drewa T., Musiałkiewicz D., Olszewski K.: Acta Pol. Pharm. Drug Res. 61, 31 (2004).
16. Drewa T., Styczyński J., Szczepanek J.: Acta Pol. Pharm. Drug Res. 65, 493 (2008).
17. Srivastava R.: in Apoptosis, Cell Signaling, and Human Diseases. Humana Press, Totowa 2007.
18. Calabrase E.J., Baldwin L.A.: Trends Pharmacol. Sci. 22, 285 (2001).
19. Gürbay A., Hinca F., Favier A.: Toxicology 229, 54 (2007).
20. Wolf M., Boutron L., Singla E.: Antimicrob. Agents Chemother. 31, 899 (1987).
21. Davey P.G., Kelly S., Varma T.R.K.: Antimicrob. Agents Chemother. 38, 1356 (1994).
22. Herold C., Ocker M., Ganslmayer M. et al.: Br. J. Cancer 86, 443 (2002).
23. Seay T.M., Peretsman S.J., Dixon P.S.: J. Urol. 155, 757 (1996).
24. Aranha O., Wood D.P., Sarkar F.H.: Clin. Cancer Res. 6, 891 (2000).
25. Kamat A.M., Lamm D.: Urology 63, 457 (2004).
26. Mondal E.R., Das S.K., Mukherjee P.: Asian Pac. J. Cancer Prev. 5, 196 (2004).
27. Concia E., Alleqranzi B., Ciottoli G.B. et al.: Clin. Pharmacokinet. 44, 1287 (2005).
28. Multhaupt H.A.B., Alvarez J.C., Rafferty P.A. et al.: J. Bone Joint Surg. 83A, 56 (2001).